UroGen Pharma Ltd. financial data

Symbol
URGN on Nasdaq
Location
Ra'anana, Israel
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 494% % -34%
Quick Ratio 18% % -19%
Debt-to-equity -451% % 78%
Return On Equity 249% % -73%
Return On Assets -71% % -48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46,808,892 shares 11%
Common Stock, Shares, Outstanding 46,781,211 shares 11%
Entity Public Float $675,100,000 USD 255%
Common Stock, Value, Issued $128,000 USD 11%
Weighted Average Number of Shares Outstanding, Basic 48,057,386 shares 2.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $96,516,000 USD 8%
Cost of Revenue $11,629,000 USD 34%
Research and Development Expense $67,687,000 USD 26%
Operating Income (Loss) $133,406,000 USD -59%
Nonoperating Income (Expense) $727,000 USD -213%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $161,640,000 USD -45%
Income Tax Expense (Benefit) $3,002,000 USD -26%
Net Income (Loss) Attributable to Parent $164,642,000 USD -43%
Earnings Per Share, Basic -3 USD/shares -18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $90,039,000 USD -28%
Cash, Cash Equivalents, and Short-term Investments $127,400,000 USD -50%
Accounts Receivable, after Allowance for Credit Loss, Current $19,703,000 USD -14%
Inventory, Net $8,341,000 USD 9.8%
Assets, Current $168,546,000 USD -43%
Property, Plant and Equipment, Net $695,000 USD 14%
Operating Lease, Right-of-Use Asset $3,098,000 USD 194%
Other Assets, Noncurrent $6,759,000 USD 1727%
Assets $185,046,000 USD -39%
Accounts Payable, Current $10,279,000 USD 85%
Employee-related Liabilities, Current $11,114,000 USD 23%
Liabilities, Current $42,244,000 USD 29%
Operating Lease, Liability, Noncurrent $2,674,000 USD 1161%
Liabilities $300,454,000 USD 8.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax $23,000 USD -90%
Retained Earnings (Accumulated Deficit) $933,352,000 USD -21%
Stockholders' Equity Attributable to Parent $115,408,000 USD -552%
Liabilities and Equity $185,046,000 USD -39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $42,024,000 USD -32%
Net Cash Provided by (Used in) Financing Activities $54,657,000 USD 8046%
Net Cash Provided by (Used in) Investing Activities $25,963,000 USD -292%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 46,781,211 shares 11%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $67,953,000 USD -286%
Deferred Tax Assets, Valuation Allowance $168,555,000 USD 17%
Deferred Tax Assets, Gross $169,324,000 USD 18%
Operating Lease, Liability $3,103,000 USD 199%
Payments to Acquire Property, Plant, and Equipment $44,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $164,855,000 USD -43%
Lessee, Operating Lease, Liability, to be Paid $4,111,000 USD 275%
Property, Plant and Equipment, Gross $5,208,000 USD 8%
Operating Lease, Liability, Current $429,000 USD -48%
Lessee, Operating Lease, Liability, to be Paid, Year Two $887,000 USD 1429%
Lessee, Operating Lease, Liability, to be Paid, Year One $747,000 USD -8.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 19%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,008,000 USD 1580%
Lessee, Operating Lease, Liability, to be Paid, Year Three $821,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $122,944,000 USD 19%
Unrecognized Tax Benefits $3,800,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Four $603,000 USD
Operating Lease, Payments $220,000 USD -21%
Depreciation, Depletion and Amortization $278,000 USD -45%
Deferred Tax Assets, Net of Valuation Allowance $769,000 USD 140%
Share-based Payment Arrangement, Expense $12,132,000 USD -2.3%